Back to Research Hub
Arcus Biosciences, Inc.
RCUS
$23.64+0.32 (+1.37%)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in…
StreetsValue research for Arcus Biosciences, Inc. (RCUS)
Members get the full report for Arcus Biosciences, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.